Abstract:In recent years, multidrug-resistant pathogenic microorganisms (MDROs) have emerged as a severe threat to human health, exhibiting robust resistance to traditional antibiotics. This has created a formidable challenge in modern medicine as we grapple with limited options to combat these resilient bacteria. Despite extensive efforts by scientists to develop new antibiotics targeting these pathogens, the quest for novel antibacterial molecules has become increasingly arduous. Fortunately, nature offers a potential solution in the form of cationic antimicrobial peptides (AMPs) and their synthetic counterparts. AMPs, naturally occurring peptides, have displayed promising efficacy in fighting bacterial infections by disrupting bacterial cell membranes, hindering their survival and reproduction. These peptides, along with their synthetic mimics, present an exciting alternative in combating antibiotic resistance. They hold the potential to emerge as a formidable tool against MDROs, offering hope for improved strategies to protect communities. Extensive research has explored the diversity, history, and structure-properties relationship of AMPs, investigating their amphiphilic nature for membrane disruption and mechanisms of action. However, despite their therapeutic promise, AMPs face several documented limitations. Among these challenges, poor pharmacokinetic properties stand out, impeding the attainment of therapeutic levels in the body. Additionally, some AMPs exhibit toxicity and susceptibility to protease cleavage, leading to a short half-life and reduced efficacy in animal models. These limitations pose obstacles in developing effective treatments based on AMPs. Furthermore, the high manufacturing costs associated with AMPs could significantly hinder their widespread use. In this review, we aim to present experimental and theoretical insights into different AMPs, focusing specifically on antibacterial peptides (ABPs). Our goal is to offer a concise overview of peptide-based drug candidates, drawing from a wide array of literature and peer-reviewed studies. We also explore recent advancements in AMP development and discuss the challenges researchers face in moving these molecules towards clinical trials. Our main objective is to offer a comprehensive overview of current AMP and ABP research to guide the development of more precise and effective therapies for bacterial infections.

Advances in Lipid and Metal Nanoparticles for Antimicrobial Peptide Delivery

Antimicrobial Peptides against Bacterial Pathogens: Innovative Delivery Nanosystems for Pharmaceutical Applications

Nanomedicines for the Delivery of Antimicrobial Peptides (AMPs)

Antimicrobial Peptide Delivery Systems as Promising Tools Against Resistant Bacterial Infections

Nanomedicine-based antimicrobial peptide delivery for bacterial infections: recent advances and future prospects

Recent Advances and Challenges in Nanodelivery Systems for Antimicrobial Peptides (AMPs)

Targeting Multidrug Resistance With Antimicrobial Peptide-Decorated Nanoparticles and Polymers

Advanced delivery systems for peptide antibiotics

Computational Approaches for Antimicrobial Peptide Delivery

Glycosylation and Lipidation Strategies: Approaches for Improving Antimicrobial Peptide Efficacy

Advances in Antimicrobial Peptide Discovery via Machine Learning and Delivery via Nanotechnology

Metal-antimicrobial peptides combo: promising weapons to combat bacteria invaders

Design, Optimization, and Nanotechnology of Antimicrobial Peptides: from Exploration to Applications

Antimicrobial Peptides: From Design to Clinical Application

Design methods for antimicrobial peptides with improved performance

Antimicrobial Peptides: Diversity, Mechanism of Action and Strategies to Improve the Activity and Biocompatibility In Vivo

Development and challenges of antimicrobial peptide delivery strategies in bacterial therapy: A review

Recent advances in the therapeutic potential of cathelicidins

Engineering Approaches for the Development of Antimicrobial Peptide-Based Antibiotics

Dealing with MDR bacteria and biofilm in the post-antibiotic era: Application of antimicrobial peptides-based nano-formulation

Advancements in peptide-based antimicrobials: A possible option for emerging drug-resistant infections